Professor Will Steward

Professor of Clinical OncologyPicture of Professor Will Steward

Contact Details

  • Tel: 0116 258 7597 or 0116 223 1857
  • Office: Osborne Building, Leicester Royal Infirmary, Leicester LE1 5WW


  • MB, ChB (Manchester)
  • MRCP (U.K.)
  • Ph.D. (Manchester)
  • JCHMT accreditation in General (Internal) Medicine and Medical Oncology
  • FRCP (Glasgow)
  • FRCP (Canada)
  • Subspecialty accreditation in Medical Oncology (Royal College Physicians and Surgeons of Canada)
  • FRCP (London) 


Will Steward’s research interests involve the clinical evaluation of novel therapies which may reduce cancer incidence or treat advanced disease.   His background was with the New Drug Development units at the Christie Hospital in Manchester, Beatson Oncology Centre in Glasgow and as Co-Director of New Drug Development at the National Cancer Institute of Canada. 

He has longstanding experience of designing and running clinical trials of new drugs in cancer with particular focus on novel agents affecting tumour biology - particularly angiogenesis inhibitors and small molecule signal transduction inhibitors.  Clinical expertise in the management of colorectal hepatobiliary, and pancreas tumours and neuroendocrine tumours.  Extensive experience with organising and running clinical trials in these diseases and currently Chair of the NCRI Colorectal Cancer Clinical Studies Group.

Research Interests

As a member of the Chemoprevention Group, this background has been utilised for planning early phase chemoprevention trials predominently involving phytochemicals derived from dietary components.  Emphasis has been on colorectal cancer prevention.  Focus to date has been examining potential role of curcumin, theaflavins, resveratrol, anthocyanins and other agents using preclinical models to indicate potential preventative efficacy, in vitro assessment of mechanisms of effect, and subsequent pilot and phase I studies in humans.  Novel strategies for choosing agents to take into trials have been developed through CRUK programme grant funding.

Work on structure/activity relationship has shown the importance of level of O-methylation of the phenol ring in determining systemic levels of polyphenolic agents and associated preventative activity. 

Current research is focussing on optimal dose and is comparing the biological effects of dietary relevant doses compared with much higher pharmacological dosing.  This will address the fundamental concern that current clinical trials in chemoprevention of agents chosen from epidemiological studies of diet then administer doses which are much higher than would be achieved from the diet.  Research also includes identification of biomarkers and predictive models of chemopreventive efficacy with the aim of allowing choice of optimal agents to take forward into clinical testing, and also being able to incorporate these into clinical trials to determine potential activity earlier than would be the case if development of cancer was the endpoint.


To view Professor Steward's publications, please use the link: PubMed Publication Listing.

Share this page:


Powerful pre-clinical platform for anti-cancer drug and biomarker discovery

Pre-clinical models that can accurately predict outcomes in the clinic are much sort after in the field of cancer drug discovery and development.  Read about how patient derived explants offer many advantages and are the powerful model of choice. A copy of the review, published in the British Journal of Cancer, is available by clicking this link: PDE Platform


SEND Study Success

Congratulations to Chris Avery, who with collaborating colleagues published findings of the SEND study, a multi-centre randomised trial using two different surgical protocols for mouth cancer treatment.  A nationwide first for this type of trial, using real-world data.  The paper, published in the British Journal of Cancer, is available by clicking this link: SEND Paper


Centre Health and Wellbeing Group
Join up for a walk on the park Friday lunchtime - details here.

More information from Jenny McNair

Contact Details

Leicester Cancer Research Centre
Robert Kilpatrick Clinical Sciences Building
University of Leicester
Leicester Royal Infirmary
Leicester LE2 7LX

T: +44 (0) 116 252 3170

(Please note this email address should not be used for clinical referrals or patient correspondence)

Maps and Directions

Sat Nav users: 


AccessAble logo

The University of Leicester is committed to equal access to our facilities. DisabledGo has a detailed accessibility guide for the Robert Kilpatrick Clinical Sciences Building.